Pharma & Biotech - Page 20

The pharmaceutical industry has reached a pivotal moment at the midpoint of 2026, shaped by an accelerating dealmaking environment and rapidly shifting patient access dynamics. A widening gap in patient affordability is

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction creating a major central nervous system biopharmaceutical company. The combined entity will generate approximately $2.2 billion in annual revenue,

The Section 232 pharmaceutical tariff regime is no longer a looming threat for the industry — it is now active law following the July 31, 2026, deadline. President Trump’s April 2, 2026,

A potential merger between AstraZeneca and Bristol Myers Squibb has been circulating on Wall Street, and the numbers involved are staggering. The Financial Times reported that the two pharmaceutical giants have held

Sanofi’s new chief executive Belén Garijo has spoken publicly for the first time about her plans to turn around the French pharmaceutical giant’s recent run of clinical disappointments. Garijo outlined a strategic

Viatris has received a formal rebuke from the US Food and Drug Administration over a direct-to-consumer video that allegedly misled viewers about the use of a cystic fibrosis inhaler. The FDA sent

Eli Lilly and contract manufacturer Resilience have committed $750 million to significantly expand production of Lilly’s KwikPen injectable device across its diabetes and obesity medicine portfolio. The investment will fund major upgrades

Four Democratic senators are demanding answers from Health and Human Services Secretary Robert F. Kennedy Jr. over potential conflicts of interest tied to a recent Merck settlement. Merck & Co. (MRK) agreed

Amgen (AMGN) has teamed up with YouTube megastar MrBeast to raise awareness and funding for pediatric cancer research through a high-profile video campaign. The collaboration was featured in MrBeast’s video titled “I

Sanofi (SNY) chief executive Belén Garijo has used her first earnings call as CEO to lay out an ambitious vision for reversing the French pharmaceutical giant’s recent fortunes. Garijo, who previously led